Key Insights

Highlights

Success Rate

85% trial completion

Published Results

37 trials with published results (6%)

Research Maturity

216 completed trials (36% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

6.3%

38 terminated out of 600 trials

Success Rate

85.0%

-1.5% vs benchmark

Late-Stage Pipeline

13%

80 trials in Phase 3/4

Results Transparency

17%

37 of 216 completed with results

Key Signals

37 with results85% success38 terminated

Data Visualizations

Phase Distribution

370Total
Not Applicable (187)
Early P 1 (5)
P 1 (43)
P 2 (55)
P 3 (41)
P 4 (39)

Trial Status

Completed216
Unknown196
Recruiting65
Not Yet Recruiting50
Terminated38
Active Not Recruiting17

Trial Success Rate

85.0%

Benchmark: 86.6%

Based on 216 completed trials

Clinical Trials (600)

Showing 20 of 20 trials
NCT07612670Not Yet Recruiting

A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy

NCT07852416Not ApplicableNot Yet RecruitingPrimary

Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy

NCT07585890Recruiting

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe

NCT07325526Phase 2RecruitingPrimary

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT06084234Phase 4Recruiting

National Liver Cancer Screening Trial

NCT05516498Phase 2TerminatedPrimary

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT06469489CompletedPrimary

Safety and Adequacy of Trans-jugular Liver Biopsy in Patients With Liver Disease: SAFE-TJLB Study

NCT07347275Not ApplicableRecruiting

A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.

NCT07830303Phase 4Not Yet RecruitingPrimary

Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis

NCT07374185Not ApplicableRecruitingPrimary

Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis

NCT07116096Not ApplicableRecruitingPrimary

Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis

NCT05895136Phase 2RecruitingPrimary

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

NCT06855056CompletedPrimary

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

NCT07811687RecruitingPrimary

Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function

NCT06832826CompletedPrimary

Colonic Polypectomy in Cirrhotic Patients With Portal Hypertension

NCT07799948Not ApplicableRecruiting

Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPS

NCT07793279Not Yet Recruiting

Hypothyroidism and Liver Fibrosis Severity in MASLD

NCT07252401Not ApplicableNot Yet RecruitingPrimary

Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction

NCT07777705Not Yet RecruitingPrimary

Application of Different Scores in Predicting Outcomes of Cirrhotic Patients Awaiting Liver Transplantation

NCT04874428Phase 1RecruitingPrimary

Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis

Scroll to load more

Research Network

Activity Timeline